228 related articles for article (PubMed ID: 17337182)
1. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
[TBL] [Abstract][Full Text] [Related]
2. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
[TBL] [Abstract][Full Text] [Related]
3. Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Jiang W; Sui Z; Macielag MJ; Walsh SP; Fiordeliso JJ; Lanter JC; Guan J; Qiu Y; Kraft P; Bhattacharjee S; Craig E; Haynes-Johnson D; John TM; Clancy J
J Med Chem; 2003 Jan; 46(3):441-4. PubMed ID: 12540243
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
Pissarnitski D
Med Res Rev; 2006 May; 26(3):369-95. PubMed ID: 16388517
[TBL] [Abstract][Full Text] [Related]
5. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
6. Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction.
Giovannoni MP; Vergelli C; Biancalani C; Cesari N; Graziano A; Biagini P; Gracia J; Gavaldà A; Dal Piaz V
J Med Chem; 2006 Aug; 49(17):5363-71. PubMed ID: 16913726
[TBL] [Abstract][Full Text] [Related]
7. SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
Pissarnitski DA; Asberom T; Boyle CD; Chackalamannil S; Chintala M; Clader JW; Greenlee WJ; Hu Y; Kurowski S; Myers J; Palamanda J; Stamford AW; Vemulapalli S; Wang Y; Wang P; Wu P; Xu R
Bioorg Med Chem Lett; 2004 Mar; 14(5):1291-4. PubMed ID: 14980684
[TBL] [Abstract][Full Text] [Related]
8. JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
Qiu Y; Bhattacharjee S; Kraft P; Mathew John T; Haynes-Johnson D; Jiang W; Sui Z; Lundeen S
Int J Impot Res; 2006; 18(5):477-83. PubMed ID: 16528290
[TBL] [Abstract][Full Text] [Related]
9. A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
Allerton CM; Barber CG; Beaumont KC; Brown DG; Cole SM; Ellis D; Lane CA; Maw GN; Mount NM; Rawson DJ; Robinson CM; Street SD; Summerhill NW
J Med Chem; 2006 Jun; 49(12):3581-94. PubMed ID: 16759100
[TBL] [Abstract][Full Text] [Related]
10. Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction.
Jiang W; Guan J; Macielag MJ; Zhang S; Qiu Y; Kraft P; Bhattacharjee S; John TM; Haynes-Johnson D; Lundeen S; Sui Z
J Med Chem; 2005 Mar; 48(6):2126-33. PubMed ID: 15771456
[TBL] [Abstract][Full Text] [Related]
11. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
[TBL] [Abstract][Full Text] [Related]
12. Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Sui Z; Guan J; Macielag MJ; Jiang W; Zhang S; Qiu Y; Kraft P; Bhattacharjee S; John TM; Haynes-Johnson D; Clancy J
J Med Chem; 2002 Sep; 45(19):4094-6. PubMed ID: 12213052
[TBL] [Abstract][Full Text] [Related]
13. Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses.
Yang GF; Lu HT; Xiong Y; Zhan CG
Bioorg Med Chem; 2006 Mar; 14(5):1462-73. PubMed ID: 16263288
[TBL] [Abstract][Full Text] [Related]
14. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
Mehrotra N; Gupta M; Kovar A; Meibohm B
Int J Impot Res; 2007; 19(3):253-64. PubMed ID: 16988721
[TBL] [Abstract][Full Text] [Related]
15. New achievement and novel therapeutic applications of PDE5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(3 Suppl):45-50. PubMed ID: 16042360
[TBL] [Abstract][Full Text] [Related]
16. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
17. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
18. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
[TBL] [Abstract][Full Text] [Related]
19. Emergence and success of PDE5 inhibitors as effective therapy for erectile dysfunction.
Manganiello V
Int J Impot Res; 2004 Jun; 16 Suppl 1():S1-3. PubMed ID: 15224126
[No Abstract] [Full Text] [Related]
20. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
